Rhythm Pharmaceuticals (RYTM) Capital Leases (2019 - 2022)

Rhythm Pharmaceuticals (RYTM) has 4 years of Capital Leases data on file, last reported at $1.8 million in Q1 2022.

• Capital Leases for Q1 2022 came in at $1.8 million, down 25.98% year-over-year; the trailing twelve-month figure through Mar 2022 was $1.8 million (down 25.98% YoY), and the FY2021 annual result was $1.9 million, down 23.76% from the prior year.
• Capital Leases fell to $1.8 million in Q1 2022 per RYTM's latest filing, from $1.9 million in the prior quarter.
• Over five years, Capital Leases peaked at $3.4 million in Q1 2019 and troughed at $1.8 million in Q1 2022.
• A 4-year average of $2.6 million and a median of $2.6 million in 2020 frame the typical range for Capital Leases.
• The sharpest annual moves came in 2020 and 2022: Capital Leases decreased 15.1% in 2020, then fell 25.98% in 2022.
• A 4-year view of Capital Leases shows it stood at $3.1 million in 2019, then fell by 17.34% to $2.6 million in 2020, then decreased by 23.76% to $1.9 million in 2021, then retreated by 8.43% to $1.8 million in 2022.
• Business Quant data shows RYTM's Capital Leases at $1.8 million in Q1 2022, $1.9 million in Q4 2021, and $2.1 million in Q3 2021.